We keep our HOLD but reduce our target price from €12.5 to €11.5 following Sligro's weak 1H25 results. We continue to view the equity story as a margin recovery play but note that improvements in FY25F are expected to remain modest with the company guiding for a 5.5-6.0% EBITDA margin, well below the Street's expectations. We therefore reduce our EBIT forecast by 36/23% in FY25F and FY26F respectively. Sligro's balance sheet offers limited room for inorganic growth or for more cash return to sha...
Aalberts: First hydronic flow control takeover in US; Ahold Delhaize: Preview 2Q25; EVS: Wins 2026 world cup contract Big Event Rental; Exor: A tad more Philips; Via Transportation reviving IPO plans; Heijmans: 1H25 preview; looks to be on track; KPN: 2Q25 preview; Montea: €24m acquisition in Dutch logistics hotspot; Ontex: Peer Essity 2Q25 results; RELX: 1H25 preview; Sligro: Weak 1H25 calls for 7.5% downgrade to consensus at EBITDA level; Events Calendar
Floridienne reported, without giving exact numbers, 1Q25 sales growth driven by the exceptional momentum of Biotrop. recording a significant increase in both revenue and profitability thanks to the success of its biological solutions for open-field crops in the Brazilian market. At the same time BioFirst (previously known as BioBest) saw increased competition in North America in the greenhouse cultivation segment, impacting the profitability of its legacy activities. We maintain our € 835 TP and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.